Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q3 2023 Results Conference Call October 30, 2023 8:00 AM ET

Company Participants

Jen Larson - SVP, Finance and IR

Steve Hoerter - President and CEO

Matt Sherman - Chief Medical Officer

Dan Martin - Chief Commercial Officer

Margarida Duarte - Head, International

Tucker Kelly - CFO

Conference Call Participants

Tyler Van Buren - TD Cowen

Eun Yang - Jefferies

Michael Schmidt - Guggenheim

Christopher Raymond - Piper Sandler

Andrew Berens - Leerink Partners

Bijan Mekoba - Stifel

Reni Benjamin - JMP Securities

Peter Lawson - Barclays

Operator

Good morning, everyone, and welcome to the Deciphera Pharmaceuticals MOTION Top Line Data and Third Quarter 2023 Conference Call. Today’s call is being recorded.

At this time, I would like to turn the call over to Jen Larson, Senior Vice President of Finance and Investor Relations. Jen?

Jen Larson

Thank you, operator. Welcome, and thank you all for joining us today. I’m Jen Larson, Senior Vice President of Finance and Investor Relations. With me this morning to discuss the Vimseltinib data and our third quarter financial results and to provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; Dan Martin, Chief Commercial Officer; Margarida Duarte, Head of International; and Tucker Kelly, our Chief Financial Officer.

Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples include our expectations of our preclinical and clinical programs, including Vimseltinib, our commercialization of QINLOCK and corporate guidance. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include those set forth in our most recent quarterly report on Form 10-Q as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements. Following this call, a replay will be available on the company’s website, www.deciphera.com.

With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?

Steve Hoerter

Thank you, Jen, and good morning, everyone. Thank you for joining us today.

We’re thrilled to host this morning’s call to review the exceptional top line results from the pivotal MOTION Phase III study of Vimseltinib in TGCT that we announced earlier today as well as compelling updated data from the Vimseltinib Phase I/II study. This morning, we also announced our third quarter financial results, showcasing record QINLOCK sales. The MOTION study was a resounding success, achieving its primary and all key secondary endpoints showing that Vimseltinib has the potential to offer substantial benefits to TGCT patients across a wide range of clinical measures and patient-reported outcomes with a favorable safety profile.